Can a Shadow on the Lung Be Nothing?

Most shadows found on lung imaging turn out to be harmless. A pooled analysis of studies estimates that roughly one in four adults who get a chest CT scan will have at least one pulmonary nodule, and the vast majority of those nodules are benign.¹ Infections, scar tissue, benign tumors, and even normal blood vessels viewed at an odd angle can all cast a shadow that looks suspicious on a chest X-ray or CT. That said, the word “nothing” oversimplifies things. A benign shadow still has a cause, and figuring out what that cause is often requires follow-up imaging, sometimes over months or years.

Why Lung Shadows Are So Common

Modern CT scanners are extraordinarily sensitive. They pick up tiny details that older chest X-rays would miss entirely. Older radiographic techniques had real physical limits on how thin a layer of tissue could produce a visible shadow, so small nodules simply went undetected.² Now, CT scans ordered for entirely unrelated reasons, such as heart-related imaging, routinely catch nodules in the lungs as incidental findings. A review of 24 studies encompassing over 30,000 participants found that pulmonary nodules were common incidental discoveries on scans originally ordered for non-cancer purposes, and the reported rate depended heavily on how much of the chest the scan covered and how small a nodule the radiologist chose to report.³

The practical effect is that millions of people now learn they have a “spot” or “shadow” on their lung without any symptoms. The overwhelming majority of those spots are not cancer. But the finding kicks off a process of evaluation that can stretch for months, and understanding what that process looks like can make it far less frightening.

What Benign Shadows Actually Are

There is no single thing called “a benign lung shadow.” The term covers a wide range of causes, from old infections to harmless growths to leftover scar tissue. The most common categories include:

Healed infections: Bacteria, fungi, and viruses can leave behind small scars or granulomas in the lungs. Fungal infections like histoplasmosis are a classic example. A person who lived in or traveled through an area where histoplasmosis is common may have calcified nodules in their lungs without ever having had obvious symptoms.⁴ Tuberculosis can leave similar calling cards.
Hamartomas: These are the most common benign lung tumors. They are disorganized clumps of normal tissue, mostly cartilage and fat. On imaging, they sometimes show a distinctive “popcorn” calcification pattern or fat density, both of which are strong clues that the nodule is harmless. In one series of 59 hamartoma cases, about 27% showed calcification and roughly 36% showed fat on imaging.⁵
Scar tissue and collapsed lung: Rounded atelectasis is an unusual form of lung collapse where a portion of lung folds in on itself near thickened or scarred tissue lining the lung. On a scan it can look alarmingly like a mass, and it is sometimes mistaken for cancer.⁶
Lymph nodes and blood vessels: Intrapulmonary lymph nodes, especially ones sitting along the fissures that divide the lung lobes, frequently appear as small, solid nodules on CT. Prominent blood vessels viewed end-on can also look like a spot.

Exposure history matters, too. People with occupational exposure to asbestos or coal dust can develop distinctive lung changes, including ground-glass opacities and linear scarring, that show up on imaging and can look worrisome at first glance. The key point across all these categories is that a shadow has a real physical cause. It is not literally “nothing.” But in everyday conversation, when people ask whether a lung shadow can be nothing, what they really mean is: can it be something I do not need to worry about? And the answer, most of the time, is yes.

How Doctors Tell Benign From Malignant

Radiologists rely on several features of a nodule’s appearance to estimate the odds that it is cancer. Size is the most intuitive factor. Very small nodules, under about 6 millimeters, carry a low risk and often do not require any follow-up at all, according to the widely used Fleischner Society guidelines.⁷ Bigger nodules warrant closer attention, but size alone is not the whole story.

Shape and edges matter a great deal. Smooth, well-defined borders are reassuring. Spiculated margins, where the nodule looks like it has spikes radiating outward, are a red flag for malignancy. Lobulated contours and signs that the nodule is pulling on nearby blood vessels or the lung lining also raise concern.⁸ Meanwhile, the presence of fat inside a nodule is a strong indicator of a hamartoma, and certain calcification patterns, like the popcorn pattern mentioned earlier, are almost exclusively seen in benign growths.⁹ Nodules sitting right along the fissure between lung lobes, especially if they have a triangular shape, are also associated with being benign. None of these features alone gives a definitive answer, but taken together they let a radiologist form a reasonable estimate of risk.

The updated Fleischner guidelines, published in 2017, emphasize flexibility. Rather than prescribing a single rigid follow-up schedule, they give recommended ranges for when to do repeat scans and encourage clinicians to factor in individual risk, including smoking history, family history of lung cancer, and what the nodule actually looks like.¹⁰ When those guidelines are explicitly included in a radiology report, patients are more likely to receive the recommended follow-up care, which suggests that the system works better when the information flows clearly.¹¹

The Ground-Glass Question

Some lung shadows do not appear as solid white spots on a CT scan. Instead, they look like hazy, translucent patches, which radiologists call ground-glass opacities. These can be benign. Infections, inflammation, and even small areas of bleeding can produce that hazy look. But ground-glass opacities deserve special attention because they are also a hallmark of a specific type of early lung cancer: adenocarcinoma and its precursor lesions.¹²

The tricky part is that even when a ground-glass opacity does represent an early adenocarcinoma, many of these are extremely slow-growing. A purely ground-glass nodule without any solid component often reflects in-situ or minimally invasive disease that may take years to progress, if it progresses at all.¹³ When a solid component begins to appear within a ground-glass nodule, that is a stronger signal that the lesion is becoming invasive. Features like irregular shape, lobulated or spiculated edges, and higher density on imaging tend to distinguish invasive adenocarcinoma from its more indolent precursors.¹⁴ The upshot: a ground-glass finding is not an automatic cancer diagnosis, but it is one type of shadow that doctors are more cautious about dismissing.

When a PET Scan Gets It Wrong

If a nodule looks concerning enough on CT, doctors may order a PET scan, which uses a radioactive sugar tracer to highlight metabolically active tissue. Cancer cells tend to gobble up sugar faster than normal cells, so they light up. But PET scans are imperfect tools for lung nodules. In one study, the false positive rate of PET-CT for lung lesions was about 6.5%, with inflammatory pseudotumors and tuberculomas being the most common benign conditions mistakenly flagged as cancer.¹⁵ Active infections and areas of inflammation soak up the tracer just like tumors do.

The reverse problem exists too. Some genuine cancers, particularly small, well-differentiated adenocarcinomas and peripheral lung cancers, do not take up enough tracer to light up clearly. One analysis of 298 patients found that PET-CT had a specificity of only 38% for pulmonary nodules, meaning it incorrectly flagged a large proportion of benign nodules, and its ability to rule out cancer in nodules that did not light up was also poor.¹⁶ Because of these limitations, radiologists weigh PET results alongside a patient’s clinical history and the nodule’s CT appearance before recommending next steps. A biopsy may still be needed even when PET results look reassuring, and a hot PET scan does not always mean cancer.¹⁷

Nodules in People Who Already Have Cancer

Finding a lung shadow is extra anxiety-inducing for someone who has been treated for cancer elsewhere in the body. The instinct is to assume the cancer has spread. But the assumption is often wrong. In a study of 228 patients with a non-lung cancer who had pulmonary nodules biopsied, about 26% turned out to have a brand-new primary lung cancer rather than a metastasis, and nearly 10% had no cancer at all on biopsy.¹⁸ In patients with a history of breast cancer specifically, a solitary lung nodule was more likely to be a new primary lung tumor than a breast metastasis.¹⁹

The original cancer type matters. Patients with melanoma, sarcoma, or testicular cancer were more likely to have a solitary lung metastasis than a new lung cancer, while patients with other cancer types often had the opposite pattern.²⁰ Multiple nodules and signs of cavitation or tissue death within the nodule tipped the odds toward metastatic disease. The practical lesson: even when cancer history is present, a lung shadow is not automatically a sign that the disease has spread. It still needs to be evaluated on its own terms.

The Biopsy Question and Its Risks

When imaging alone cannot settle the question, a tissue sample is the gold standard. The most common approach for a peripheral lung nodule is CT-guided needle biopsy, where a radiologist inserts a thin needle through the chest wall and into the nodule while watching on a real-time CT image. It is effective, but it carries a real risk of pneumothorax, a partial collapse of the lung caused by air leaking through the puncture. The reported incidence ranges widely, from roughly 9% to as high as 54%, with an average around 20%.²¹ Most cases of biopsy-related pneumothorax are small and resolve on their own or with a temporary chest tube, but the risk is part of why doctors do not rush to biopsy every small nodule they find. For low-risk nodules, watching and waiting with repeat scans is often the safer bet.

Newer Tools for Sorting Nodules

Researchers are actively trying to develop blood tests and software that could better distinguish benign from malignant nodules without requiring a biopsy. Results so far are mixed.

One blood test, EarlyCDT Lung, looks for autoantibodies that the immune system makes in response to certain tumor proteins. The idea is promising, but a systematic review found the test had a sensitivity of only about 20%, meaning it missed about four out of five cancers it was supposed to detect. Its specificity was better, around 92%, so a positive result was somewhat informative, but its low sensitivity limits its usefulness as a standalone tool.²² A different approach, using a panel of four blood proteins combined with nodule size, showed more encouraging results, increasing sensitivity at high specificity levels compared to using size alone.²³ Another test, LungLB, which looks for genetically abnormal cells circulating in the blood, achieved about 77% sensitivity and 72% specificity in one study, and performed reasonably well across different patient subgroups.²⁴

On the imaging side, artificial intelligence systems are being trained to analyze CT scans and classify nodules. One AI system achieved an overall accuracy of about 76% in distinguishing benign from malignant nodules, with better performance on subsolid nodules (about 81% accuracy) than on solid ones (about 67%).²⁵ These numbers are not yet good enough to replace a radiologist’s judgment, but they hint at a future where software provides a useful second opinion. None of these tools are currently used as the sole basis for deciding whether to biopsy or watch a nodule. They are add-ons to the existing process, not replacements for it.

The Anxiety Problem

Perhaps the most underappreciated part of finding a lung shadow is what it does to a person’s mental health. Being told you have a “spot on your lung” is terrifying, even when the odds strongly favor a benign explanation. In one study of 182 patients with incidental pulmonary nodules, nearly 60% screened positive for anxiety.²⁶ That anxiety is not irrational, exactly. The uncertainty is real. But it is often out of proportion to the statistical risk, especially for small, smooth nodules in people who have never smoked.

The watch-and-wait approach, where you get a follow-up scan in three, six, or twelve months, is medically sound but psychologically brutal. Patients sometimes describe it as living under a cloud. Some push for an early biopsy just to resolve the uncertainty, even when the risk-benefit math does not support it. This is one area where a clear conversation with your doctor about the actual probability of malignancy, stated as a number or at least a ballpark, can make a real difference. If you are told your nodule has a less than 1% chance of being cancer, that framing is very different from “we need to keep an eye on it,” even though both statements may be describing the same clinical plan.

Overdiagnosis in Lung Cancer Screening

The flip side of finding shadows early is finding things that would never have caused harm. When high-risk adults, generally heavy smokers over a certain age, undergo low-dose CT screening for lung cancer, screening catches real cancers at earlier, more treatable stages. But it also catches some cancers that are so slow-growing they would never have caused symptoms or shortened the person’s life. This phenomenon is called overdiagnosis. An analysis of the large National Lung Screening Trial estimated that roughly 18.5% of lung cancers detected by low-dose CT screening were overdiagnosed.²⁷ For a specific subtype called bronchioloalveolar carcinoma, the overdiagnosis rate was estimated at nearly 79%.

A separate cohort study estimated that slow-growing or indolent cancers made up about a quarter of all incident cases detected through screening, and many of those may have been overdiagnosed.²⁸ Overdiagnosis matters because a diagnosis of cancer comes with real consequences. The person endures anxiety, undergoes surgery or other treatment, and faces the risks of those procedures, all for a disease that might never have bothered them. Researchers have suggested that for some of these indolent tumors, less aggressive approaches, like minimally invasive resection or even active surveillance, should be explored.²⁹ This does not mean screening is a bad idea for people who qualify, but it is an honest tradeoff that screening programs have to reckon with.

For the average person who stumbles into a lung shadow diagnosis through an unrelated scan, the overdiagnosis conversation is mostly reassuring. It means that even among shadows that do turn out to be technically cancerous, a meaningful fraction are so slow-growing that they are unlikely to ever cause trouble. The system is getting better at identifying which nodules to leave alone, but it is still a work in progress.